Phase II Study of an Omega-3 Fatty Acid in TNBC Survivors
Neil M. Iyengar, MD, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
Clinical Pearls
Neil M. Iyengar, MD, Fellow, Medical Oncology and Hematology, Breast Medicine Service, Memorial Sloan-Kettering Cancer Center, discusses a phase II study looking at an omega-3 fatty acid in triple-negative breast cancer (TNBC) survivors.
- This phase II study looks to analyze whether DHA, an omega-3 fatty acid, will reduce circulating markers of inflammation in overweight/obese patients with a history of TNBC
- In another poster, it was hypothesized that targeting the inflammation-aromatase axis with an omega-3 fatty acid could decrease the risk for relapse or development of breast cancer
- This trial will look at breast tissue pre- and post-intervention to determine if there is a decreases in inflammatory markers after 3 months of treatment with the omega-3 fatty acid
<<<
Rugo Surveys Peers on Treatment After Metastatic Relapse of HR+, HER2– Breast Cancer
April 20th 2024During a Case-Based Roundtable® event, Hope S. Rugo, MD, FASCO, moderated a discussion on treatment options for a patient whose breast cancer recurred several years after adjuvant therapy.
Read More
PTCy Offers New Hope for Mismatched Stem Cell Transplants in Leukemia, MDS
April 13th 2024Jeff Auletta, MD, discussed how PTCy-based graft-vs-host disease prophylaxis offers a promising approach for expanding access to successful cell transplantation regardless of donor match or patient ethnicity.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
UGT1A1 Status Underutilized in Predicting Sacituzumab Toxicity in MBC
April 8th 2024During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the value of testing for UGT1A1 status in patients receiving sacituzumab govitecan for hormone receptor–positive breast cancer in the second article of a 2-part series.
Read More
